Ascendis Pharma A/S (ASND)
229.23
+6.54
(+2.94%)
USD |
NASDAQ |
Oct 09, 16:00
229.24
+0.01
(+0.00%)
After-Hours: 20:00
Ascendis Pharma Cash from Investing (Quarterly) : -3.268M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.268M |
| March 31, 2026 | -7.900M |
| December 31, 2025 | -3.918M |
| September 30, 2025 | -0.2384M |
| June 30, 2025 | -4.973M |
| March 31, 2025 | -0.7399M |
| December 31, 2024 | -0.6389M |
| September 30, 2024 | -0.519M |
| June 30, 2024 | 0.619M |
| March 31, 2024 | 7.766M |
| December 31, 2023 | 3.243M |
| September 30, 2023 | 25.31M |
| June 30, 2023 | 53.11M |
| March 31, 2023 | 226.01M |
| December 31, 2022 | -2.178M |
| September 30, 2022 | 13.53M |
| June 30, 2022 | 9.810M |
| March 31, 2022 | 43.24M |
| December 31, 2021 | -132.45M |
| September 30, 2021 | 24.59M |
| June 30, 2021 | 13.30M |
| March 31, 2021 | -36.28M |
| December 31, 2020 | -84.98M |
| September 30, 2020 | 22.31M |
| June 30, 2020 | -262.52M |
| Date | Value |
|---|---|
| March 31, 2020 | -6.765M |
| December 31, 2019 | -1.242M |
| September 30, 2019 | -1.393M |
| June 30, 2019 | -0.3365M |
| March 31, 2019 | -2.804M |
| December 31, 2018 | -1.245M |
| September 30, 2018 | -1.364M |
| June 30, 2018 | -0.4031M |
| March 31, 2018 | -0.1254M |
| December 31, 2017 | -0.2864M |
| September 30, 2017 | -0.1511M |
| June 30, 2017 | -0.2243M |
| March 31, 2017 | -0.4001M |
| December 31, 2016 | -0.1152M |
| September 30, 2016 | -0.173M |
| June 30, 2016 | -0.3079M |
| March 31, 2016 | -0.1521M |
| December 31, 2015 | -0.4064M |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | -0.0408M |
| September 30, 2014 | -0.0804M |
| June 30, 2014 | -0.2447M |
| March 31, 2014 | -0.1713M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | -5.102B |
| Novo Nordisk A/S | -2.009B |
| Evaxion AS | -- |
| Genmab A/S | 2.026M |
| Zealand Pharma A/S | 34.81M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 327.52M |
| Cash from Financing (Quarterly) | -53.34M |
| Free Cash Flow | 388.83M |
| Free Cash Flow Per Share (Quarterly) | 4.740 |
| Free Cash Flow to Equity (Quarterly) | 842.38M |
| Free Cash Flow to Firm (Quarterly) | 338.61M |
| Free Cash Flow Yield | 2.66% |